Artios Reports First Clinical Data for DNA Polymerase Theta Inhibitor ART6043 at ESMO 2025
核心洞察
Artios presented first-in-human clinical data for ART6043, a potential first-in-class DNA polymerase theta (搜索) inhibitor, showing an attractive tolerability profile and promising clinical signals in advanced solid tumors (搜索).
The Phase 1/2a study enrolled 61 patients with advanced solid tumors (搜索), demonstrating that ART6043 can be dosed orally once daily with no drug-drug interaction when combined with olaparib.
Pharmacodynamic data showed enhanced target engagement when ART6043 was combined with olaparib, similar to preclinical models where tumor regressions were observed.
Artios Pharma presented the first clinical data for its DNA polymerase theta (搜索) (Polθ (搜索)) inhibitor ART6043 at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, marking a significant milestone as the first therapeutic candidate targeting Polθ to demonstrate clinical activity in humans.
The Phase 1/2a study (NCT05898399) evaluated ART6043 both as monotherapy and in combination with the PARP (搜索) inhibitor olaparib in patients with advanced solid tumors (搜索) harboring DNA damage response pathway mutations. Dr. Timothy A. Yap from The University of Texas MD Anderson Cancer Center presented the results, which showed an attractive tolerability profile and promising clinical signals.
Study Design and Patient Population
The trial enrolled 61 patients across two treatment arms: 19 patients received ART6043 monotherapy with a median age of 58 years, while 42 patients received the combination therapy with a median age of 65.5 years. Notably, 37% of monotherapy patients and 31% of combination therapy patients had prior treatment with PARP (搜索) inhibitors. All patients had received a median of 4 prior therapies, highlighting the advanced nature of their cancers.
Safety and Pharmacokinetic Profile
ART6043 demonstrated an expected, benign tolerability profile as monotherapy, with no additional toxicity observed when combined with olaparib. The pharmacokinetic data support convenient oral once-daily dosing, and importantly, no drug-drug interaction between ART6043 and olaparib was detected.
"The emerging clinical data validate our approach to inhibit Polθ (搜索) to selectively cripple tumor cells and exploit a cancer (搜索)'s dependency on DNA repair," said Ian Smith, Chief Medical Officer of Artios. "The initial data and efficacy signals in the relevant genetic background are encouraging, and we look forward to advancing ART6043's clinical development to realize its potential to increase the effectiveness of PARP (搜索) inhibition, where resistance to standard of care has become increasingly prevalent."
Mechanism of Action and Target Engagement
ART6043 targets Polθ (搜索), a key DNA repair enzyme that is overexpressed in many cancers but present at low levels or absent in most healthy tissues. Cancer (搜索) cells rely on Polθ as a backup DNA repair mechanism when their primary homologous recombination DNA repair pathway is defective or when they acquire resistance to DNA-damaging therapies such as PARP (搜索) inhibitors.
The pharmacodynamic data revealed that target engagement of ART6043 alone was enhanced when combined with olaparib in patients, mirroring preclinical models where tumor regressions were observed. This enhanced engagement suggests the combination approach may overcome resistance mechanisms that limit single-agent PARP (搜索) inhibitor efficacy.
Clinical Significance and Future Development
Dr. Yap emphasized the clinical need addressed by this novel approach: "The first-in-class Polθ (搜索) inhibitor, ART6043, represents a much-needed therapeutic option for patients with advanced, hard-to-treat cancers where resistance to existing treatments is a major clinical challenge. The initial clinical signals observed to date reinforce the potential of ART6043 to address this significant unmet need for patients who currently have limited treatment options."
The results support the potential advancement of ART6043 into Phase 2 clinical development. Artios plans to evaluate the compound in dedicated Phase 2 trials to assess efficacy across molecularly selected cohorts and explore expansion into new combinations and disease settings.
Targeting DNA Damage Response Pathways
ART6043 represents Artios' differentiated approach to targeting DNA damage response pathways. As a selective inhibitor of the polymerase domain of DNA polymerase theta (搜索), the compound targets microhomology-mediated end joining (MMEJ) to exploit tumor dependence on error-prone DNA repair. This mechanism provides broad rationale for use both as monotherapy and in combination with PARP (搜索) inhibition and other DNA-damaging modalities.
The company's strategy focuses on molecularly defined solid tumors, including settings with BRCA (搜索) variants and PARP (搜索) inhibitor resistance, aiming to enhance target engagement and anti-tumor activity while maintaining tolerability. This precision approach addresses a critical gap in current cancer (搜索) treatment, where resistance to PARP inhibitors has become increasingly prevalent in clinical practice.